AMDL, Inc. to Be Featured on Steve Crowley's American Scene on Business Talk Radio Network
November 08 2004 - 6:00AM
PR Newswire (US)
AMDL, Inc. to Be Featured on Steve Crowley's American Scene on
Business Talk Radio Network TUSTIN, Calif., Nov. 8 /PRNewswire/ --
The daily Investors' Showcase segment of "Steve Crowley's American
Scene" radio program, syndicated nationally by the Business Talk
Radio Network, today announced that AMDL, Inc. (AMEX:ADL),
developer and marketer of tests for the early detection of cancer
and other serious diseases, will be featured on the program. Steve
Crowley's American Scene (http://www.americansceneradio.com/) is
broadcast for two hours every weekday between the hours of 9 a.m.
and 11 a.m. Eastern time and 6 a.m. and 8 a.m. Pacific. It airs in
major markets including New York, Washington, DC, Chicago,
Minneapolis, Los Angeles, San Diego, Portland, St. Louis and many
other cities nationally. This financial talk radio program was
launched in June 1990, and is hosted by Steve Crowley, the former
Money Editor of ABC's "Good Morning America" and author of Money
For Life, published by Simon & Schuster. Live interviews with
Gary Dreher, AMDL's CEO, will be featured on the program twice
weekly for the next six weeks, including on Tuesday, November 9 and
Thursday, November 11. For more information, please contact Paul
Knopick, E & E Communications, 949/707-5365 or . About AMDL
AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a
theranostics company, involved in the detection and treatment of
the same disease, cancer. AMDL is the inventor, developer and
worldwide marketer through exclusive distribution agreements of the
DR-70(R) non-invasive cancer blood test, which has demonstrated its
ability to detect the presence in humans of up to 13 cancers 84
percent of the time overall. In a study published in the Journal of
Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect
at least 13 different types of cancer (lung, breast, stomach,
liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic,
thyroid, malignant lymphoma, pancreatic) although the sample size
for 9 of the cancers was not statistically significant. Clinical
trials of DR-70(R) have been conducted in Canada, China, Germany,
Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a
single tube of blood, eliminating the need for costly, multiple
tests. AMDL also owns a combination immunogene therapy technology
that is a possible treatment for those already diagnosed with
cancer and could eventually be used as a vaccine to protect
patients known to be at risk because of a family history for
certain types of cancer. The combination therapy both builds the
body's immune system and destroys cancer cells. More information
about AMDL and its additional products can be obtained at
http://www.amdlcorporate.com/. Statements in this press release may
constitute forward-looking statements and are subject to numerous
risks and uncertainties, including the failure to complete
successfully the development of new or enhanced products, the
Company's future capital needs, the lack of market demand for any
new or enhanced products the Company may develop, any actions by
the Company's partners that may be adverse to the Company, the
success of competitive products, other economic factors affecting
the Company and its markets, and other risks detailed from time to
time in the Company's filings with the Securities and Exchange
Commission. The actual results may differ materially from those
contained in this press release. DATASOURCE: E & E
Communications CONTACT: Paul Knopick of E & E Communications,
+1-949-707-5365, Web site: http://www.americansceneradio.com/ Web
site: http://www.amdlcorporate.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024